Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to announce its earnings results before the market opens on Thursday, November 1st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 137.32% and a negative return on equity of 369.13%. The business had revenue of $13.75 million for the quarter, compared to analyst estimates of $15.88 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. The firm’s quarterly revenue was up 14.1% compared to the same quarter last year. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
LXRX opened at $8.18 on Wednesday. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.68 and a current ratio of 2.71. Lexicon Pharmaceuticals has a twelve month low of $7.67 and a twelve month high of $13.97. The stock has a market capitalization of $903.15 million, a PE ratio of -6.44 and a beta of 0.35.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: What does relative strength index mean?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.